Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Locoregionally Advanced Nasopharyngeal Carcinoma

  • Yu, Hong-Sheng (Department of Oncology, the Affiliated Hospital of Medical College, Qingdao University) ;
  • Wang, Xin (Department of Otorhinolaryngology-Head and Neck Surgery, The First Hospital of Jilin University) ;
  • Song, Ai-Qin (Department of Oncology, the Affiliated Hospital of Medical College, Qingdao University) ;
  • Liu, Ning (Department of Oncology, the Affiliated Hospital of Medical College, Qingdao University) ;
  • Zhang, Wei (Department of Oncology, the Affiliated Hospital of Medical College, Qingdao University) ;
  • Yu, Li (Department of Oncology, the Affiliated Hospital of Medical College, Qingdao University)
  • Published : 2012.08.31


Objective: To compare the clinical effects of concurrent radiochemotherapy with those of radiotherapy in treating locally advanced nasopharyngeal carcinoma (Stage III~IVa). Methods: A total of 95 patients suffering from nasopharyngeal carcinoma (Stage III~IVa) were divided into two groups: concurrent radiochemotherapy (Group CCRT, n=49) and radiotherapy (Group RT, n=46). The two groups were both delivered conventional fractionated radiotherapy, while Group CCRT also received three cycles of PF (DDP+5-Fu) or PLF (DDP+5-Fu+CF) chemotherapy. Results: The complete remission rate and total remission rate of Group CCRT were higher than those of Group RT ($X^2$=4.72~7.19, P<0.05). The one-year overall survival (OS) rate calculated by the life table method, was also higher than that of Group RT ($X^2$=4.24, P<0.05) as well as the 3-year OS rate, nasopharyngeal control rate and cervical lymph nodes' control rate ($X^2$=4.28~4.40, P<0.05). In addition, the 5-year OS and metastasis-free rates of Group CCRT were higher than those of Group RT and the differences were of statistical importance ($X^2$=3.96~8.26, P<0.05). However, acute toxicity was also obviously higher, the difference in gastrointestinal reactions being statistically significant ($X^2$=11.70, P<0.05). Conclusion: This study demonstrated that concurrent radiochemotherapy could improve the remission rate, overall survival rate and locally control rate. The toxicity of concurrent radiochemotherapy could be tolerated by the patients.


  1. Baujat B, Audry H, Bourhis J, et a1 (2006). Chemotherapy in locally advanced nasopharyngeal carcinoma:An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys, 64, 47-56.
  2. Chen Y, Liu MZ, Liang SB, et al (2008). Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China. Int J Radiat Oncol Biol Phys, 71, 1356-64.
  3. Cheng SH, Tsai SY, Yen KL, et a1 (2000). Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol, 18, 2040-5.
  4. Gu XZ, Yin WB, Yu ZH, et al (2008). Cancer radiotherapeutics. Fourth Edition, Beijing: China Union Medical University Press, 2008, 477-8.
  5. Hara W, Loo BW, Goffinet DR, et al (2008). Excellent local control with stereo¬tactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys, 71, 393-400.
  6. Huang PY, Mai HQ, Luo DH, et al (2009). Induction-concurrent chemoradiotherapy versus induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Cancer, 28, 1033-42.
  7. Hu D, Cao CJ, Xie GF, et al (2007). A study of induction chemotherapy combined with radiotherapy versus concurrent radiochemotherapy for NPC. Chin J Cancer, 16, 263-6.
  8. Hui EP, Ma BB, Leung SF, et al (2009). Randomized phase II trial ofconcurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol, 27, 242-9.
  9. Kalaghchi B, Kazemian A, Hashem FA et al (2011). Chemoradiation in nasopharyngeal carcinoma: a 6-year experience in tehran cancer institute. Acta Med Iran, 49, 49-53.
  10. Lee AW, Tung SY, Chan AT, et a1 (2006). Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Badiat Oncol Biol Phys, 66, 142-51.
  11. Lee AW, Lau KY, Hung WM, et al (2008). Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyn¬geal carcinoma. Radiother Oncol, 87, 204-10.
  12. Lee N, Xia P, Quivey JM, et a1 (2002). Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma:an update of the UCSF experience. Int J Radiat Oncol Biol Phys, 5, 12-22.
  13. Lee N, Harris J, Garden AS, et al (2009). Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol, 27, 3684-90.
  14. Lin JC, Jan JS, Hsu CY, et a1 (2003). Phase III study of concurrent radiochemotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma:positive effect on overaIl and progression-free survival. J Clin Oncol, 21, 631-7.
  15. Liu XQ, Luo W, Liu MZ, et al (2008). Treatment results and prognostic analysis of 1093 primary nasopharyngeal carcinoma: the experience of a single institution of Guangzhou in the beginning of the 21st century. Chin German J Clin Oncol, 7, 187-95.
  16. Pignon JP, Bourhis J, Domenge C, et al (2000). Chemotherapy added to locoregional treatment for head and neck squamouscell carcinoma: Three meta-analyses of updated individual data. Lancet, 355, 949-55.
  17. Rottey S, Madani I, Deron P, Van Belle S (2011). Modern treatment for nasopharyngeal carcinoma: current status and prospects. Curr Opin Oncol, 23, 254-8.
  18. Shen WJ, Wang LH (2001). Radiation induced injury [M]. Beijing: Chinese Medical Science and Technology Press, 257-9.
  19. Shueng PW, Shen BJ, Wu LJ, et al (2001). Concurrent imageguided intensity modulated radiotherapy and chemotherapy following neoadjuvant chemotherapy for locally advanced nasopharyngeal carcinoma. Radiat Oncol, 6, 95.
  20. Sun Y (2003). Medical Oncology. Beijing: People's Medical Press, 432- 3.
  21. Wang J, Shi M, Hsia Y, et al (2012). Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: A pilot study. Radiat Oncol, 7, 2.
  22. Wee J (2008). Nasopharyngeal Cancer Workgroup-the past, the present and the future. Ann Acad Med Singapore. 37, 606-14.
  23. Xiao WW, Huang SM, Han F, et al (2001). Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: Long-term results of a phase 2 study. Cancer, 117, 1874-83.
  24. Yang AK, Liu TR, Guo X, Zhao XM (2008). A meta-analysis of concurrent radiochemotherapy versus radiotherapy for advanced NPC. J Otolaryngol Head Neck Surg, 43, 218-23.
  25. Zhang L, Zhao C, Ghimire B, et al (2010). The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase iii randomized trials. BMC Cancer, 10, 558.

Cited by

  1. Comparison of Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: a Meta-analysis of 793 Patients from 5 Randomized Controlled Trials vol.13, pp.11, 2012,
  2. Refractory Nasopharyngeal Carcinoma vol.149, pp.3, 2013,
  3. Comparison of Radical Cystectomy and Chemoradiotherapy in Patients with Locally Advanced Bladder Cancer vol.15, pp.16, 2014,
  4. Tumor Volume Predicts Survival Rate of Advanced Nasopharyngeal Carcinoma Treated with Concurrent Chemoradiotherapy vol.155, pp.4, 2016,
  5. Tetrandrine enhances radiosensitivity through the CDC25C/CDK1/cyclin B1 pathway in nasopharyngeal carcinoma cells vol.17, pp.6, 2018,